Search This Blog

Thursday, September 26, 2013

Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint (NYSE:LLY)

Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.